ReviewBlood cancer discovery2025

Minimal Residual Disease as an Early Endpoint for Accelerated Drug Approval in Myeloma: A Roadmap.

Ola Landgren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.